# US 2021/0277051 A1 · Compound or salt thereof and preparation method and application of same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277051 A1
- Document ID: US20210277051A1
- Status: Published application
- Kind: A1
- Application number: 17/255,074
- Filed: 2018-06-22
- Published: 2021-09-09
- Earliest claimed: 2018-06-22
- Assignees: Zhejiang Peptites Biotech Co., Ltd.
- Applicants: Zhejiang Peptites Biotech Co., Ltd.
- Inventors: Haiying XING; Zhiguo LIU; Xinyou YU; Xiaohang CHEN; Huiping WANG
- Web page: https://patentgrep.com/patent/US20210277051A1

## CPC

- C07K 1/10: using coupling agents {(C07K1/006 takes precedence)}
- C07C 39/00: Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C 217/90: the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
- C07C 271/16: to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C07C 271/22: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07D 307/79: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07K 1/042: {characterised by the nature of the carrier}
- C07K 1/063: {for alpha-amino functions}
- C07K 7/23: Luteinising hormone-releasing hormone [LHRH]; Related peptides
- C08G 69/48: Polymers modified by chemical after-treatment
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The invention relates to a compound or a salt thereof, a method for preparation thereof, and use thereof, wherein the compound has the structure of Formula (1): the substituents in Formula (1) are as defined in the specification. The compound of Formula (1) or a salt thereof can be attached to a solid-phase resin, on which solid-phase synthesis may be performed.

## Claims

### Claim 1

A compound represented by Formula (1) or a salt thereof:
in Formula (1), R1 is hydrogen or an amino-protecting group;
R2, together with the N atom R2 is attached to as an amino group, form an amino acid, or an amino acid with a protecting group, or a peptide chain formed by them;
X1 and X2 are each independently O or S;
R3 is H or a substituent containing an active group that can react with an attaching functional group on a solid-phase resin;
R4 is H or an alkyl group.

### Claim 2 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein the amino-protecting group includes Fmoc, Boc, Alloc, Dde, ivDde, Trt, Mtt or Mmt.

### Claim 3 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein the amino acid or amino acid with a protecting group is an α-amino acid or an α-amino acid with a protecting group.

### Claim 4 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R2 is
wherein P is an amino-protecting group or a hydroxyl-protecting group, and multiple Ps can be the same or different.

### Claim 5 (depends on 4)

The compound according to claim 4 or a salt thereof, wherein R2 is

### Claim 6 (depends on 5)

The compound according to claim 5 or a salt thereof, wherein R2 is

### Claim 7 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R3 is a substituent containing carboxyl, hydroxyl and/or NH2.

### Claim 8 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R3 is H or —(CH2)mCOOH, m is an integer from 1 to 10, and any one or more CH2 in the (CH2)m may have a substituent.

### Claim 9 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein R3 and X1 together form —OH, —O(CH2)mCOOH, —SH or —O(CH2)mCOOH.

### Claim 10 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein both X1 and X2 are O.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound according to claim 1 or a salt thereof, wherein Formula (1) has the following structures:
in Formulae (VI), (IX), (X) and (XII), R1-R4, X1, X2, and m are as defined in any one of claims 1-10;
R5 is selected from the group consisting of —CH2COOH, —CH2CH2COOH,
—(CH2)4NH2,
—CH2OH, —CH(OH)CH3, —CH2CONH2, —CH2CH2CONH2, —CH2SH, H, —CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH(CH3)CH2CH3, —(CH2)2SCH3,
when R5 contains a carboxyl, hydroxyl, —NH2, —NH—, sulfydryl, or guanidine group, it may be protected by a protecting group;
R6 is a carboxyl-protecting group.

### Claim 12 (depends on 1)

The compound according to claim 1 or a salt thereof, wherein Formula (1) has the following structures:

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A solid-phase resin carrying the compound of Formula (1) according to claim 1 or a salt thereof, wherein the solid-phase resin carrying the compound or a salt thereof has the following structure:
in Formula (1)-resin, represents the body of the solid-phase resin, G is a linking structure formed by a reaction between a group in R3 in Formula (1) according to claim 1 and a group on the side chain of the solid-phase resin, R′3 is the residual structure after the reaction of R3, Z is the residual structure after the reaction of the side chain of the solid-phase resin, and the definitions of the other substituents are the same as those in Formula (1); preferably, R′3-G-Z is R′3—CONH—Z, or R′3—COO—Z;
alternatively, Z is directly connected to X1 without R′3-G.

### Claim 15 (depends on 14)

The solid-phase resin according to claim 14, wherein Formula (1)-resin has the following structures:
preferably, Formula (1)-resin has the following structures:
preferably, in Formula (i)-resin to Formula (iv)-resin, and Formula (ix)-resin to Formula (x)-resin, the resin is selected from an AM resin, an MBHA resin, a Sieber resin or a Rink resin, preferably an AM resin or an MBHA resin;
preferably, in Formula (ix)-resin to Formula (x)-resin, the resin is a CTC resin.

### Claim 16 (depends on 1)

Use of the compound of Formula (1) according to claim 1 or a salt thereof or a Formula (1) resin, in the preparation of a target polypeptide or a salt thereof, wherein the C terminal of the target polypeptide contains the —NHR2 group from Formula (1); or alternatively, this —NHR2 group may be transformed into a target structure or form a ring with the rest of the polypeptide chain.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16)

The use according to claim 16, comprising the following steps:
attaching the compound of Formula (1) to a starting solid-phase resin to obtain Formula (1)-resin, or directly providing Formula (1)-resin;
in Formula (1)-resin, represents the body of the solid-phase resin, G is a linking structure formed by a reaction between a group in R3 in Formula (1) according to claim 1 any one of claims 1-12 and a group on the side chain of the solid-phase resin, R′3 is the residual structure after the reaction of R3, Z is the residual structure after the reaction of the side chain of the solid-phase resin, and the definitions of the other substituents are the same as those in Formula (1); preferably, R′3-G-Z is R′3-CONH—Z, or R′3-COO—Z;
alternatively, Z is directly connected to X1 without R′3-G,
with the proviso that: when R1 is an amino-protecting group, it is removed to expose the NH group; when R1 is hydrogen, there is no need to remove it;
preparing a peptide-resin with the peptide chain fully protected by stepwise solid-phase coupling on the exposed NH group;
cleaving the fully protected peptide chain off the peptide-resin to obtain, directly or after removing the protecting groups, the target polypeptide or a salt thereof;
optionally, before cleaving the fully protected peptide chain off the peptide-resin, using the fully protected peptide chain as a starting peptide to carryout cyclization to form a cyclic peptide; preferably, the reaction site of cyclization in the fully protected peptide chain is in R2;
wherein the Fmoc-protecting group attached to the peptide on the resin is removed before each coupling step;
when the target polypeptide is PMX-53 or a salt thereof, which is a cyclic peptide, the NR2 in the Formula (1)-resin is
wherein P1 and P2 are protecting groups, preferably, the NR2 is
Formula (1)-resin may be Formula (VI)-resin
Formula (VI)-resin may be Formula (ix)-resin
preferably, the resin in Formula (ix)-resin is a CTC resin;
more preferably, when the target polypeptide is PMX-53 or a salt thereof, the peptide-resin with the uncyclized PMX-53 fully protected is prepared b successive solid-phase coupling of the amino acids Fmoc-Trp(Boc)-OH, Fmoc-D-Cha-OH, Fmoc-Pro-OH, Fmoc-Orn(Dde)-OH, and Fmoc-Phe-OH as reaction reagents to the exposed NH2 group, followed by acetylation of the amino group of the last amino acid coupled, thereby obtaining the following peptide-resin with the uncyclized PMX-53 fully protected;
Ac-Phe-Orn(Dde)-Pro-D-Cha-Trp(Boc)-Formula (1)-resin; preferably, Ac-Phe-Orn(Dde)-Pro-D-Cha-Trp(Boc)-Formula (VI)-resin; more preferably, Ac-Phe-Orn(Dde)-Pro-D-Cha-Trp(Boc)-Formula (ix)-resin; even more preferably, Ac-Phe-Orn(Dde)-Pro-D-Cha-Trp(Boc)-Formula (ix)-CTC resin;
wherein the Fmoc-protecting group attached to the peptide on the resin is removed before each coupling step;
then the All protecting group and the Dde protecting group are removed, followed by a cyclization reaction to obtain the peptide resin with PMX-53 fully protected: Ac-Phe-c(Orn-Pro-D-Cha-Trp(Boc)-Arg(pbf))-resin, wherein the resin is preferably a CTC resin;
finally, the protecting groups are removed by cleavage to obtain PMX-53 or a salt thereof;
when the target polypeptide is Liraglutide or a salt thereof, its C terminal being —NCH2COOH, the NR2 in Formula (1)-resin is NCH2COOP, in which P is a protecting group, preferably tert-butyl; Formula (1)-resin may be Formula (VI)-resin; Formula (VD-resin may be Formula (x)-resin defined in claim 15;
preferably, the resin in Formula (x)-resin may be an AM resin, an MBHA resin, a Sieber resin, or a Rink resin, among which the first two resins are preferred;
further preferably, when the target polypeptide is Liraglutide or a salt thereof, the peptide-resin with Liraglutide fully protected is prepared by successive solid-phase coupling of the following amino acids as reaction reagents to the exposed NH2 group: moc-Arg(pbf)-OH, Fmoc-Gly-OH, Fmoc-Arg(pbf)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Lys(N-s-(Palm-Glu-Ot-Bu)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Val-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-HmbGly-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Ala-OH, Boc-His(Trt)-OH; thereby obtaining the following peptide-resin with Liraglutide fully protected;
H-His(Trt)-Ala-Glu(Ot-Bu)-HmbGly-Thr(t-Bu)-Phe-Thr(t-Bu)-Ser(t-Bu)-Asp(Ot-Bu)-Val-Ser(t-Bu)-Ser(t-Bu)-Tyr(t-Bu)-Leu-Glu(Ot-Bu)-Gly-Gln(Trt)-Ala-Ala-Lys(N-ε-(Palm-Glu-Ot-Bu))-Glu(Ot-Bu)-Phe-Ile-Ala-Trp(Boc)-Leu-Val-Arg(pbf)-Gly-Arg(pbf)-Formula (1)-resin; preferably, H-His(Trt)-Ala-Glu(Ot-Bu)-HmbGly-Thr(t-Bu)-Phe-Thr(t-Bu)-Ser(t-Bu)-Asp(Ot-Bu)-Val-Ser(t-Bu)-Ser(t-Bu)-Tyr(t-Bu)-Leu-Glu(Ot-Bu)-Gly-Gln(Trt)-Ala-Ala-Lys(N-ε-(Palm-Glu-Ot-Bu))-Glu(Ot-Bu)-Phe-Ile-Ala-Trp(Boc)-Leu-Val-Arg(pbf)-Gly-Arg(pbf)-Formula (VI)-resin; more preferably, H-His(Trt)-Ala-Glu(Ot-Bu)-HmbGly-Thr(t-Bu)-Phe-Thr(t-Bu)-Ser(t-Bu)-Asp(Ot-Bu)-Val-Ser(t-Bu)-Ser(t-Bu)-Tyr(t-Bu)-Leu-Glu(Ot-Bu)-Gly-Gln(Trt)-Ala-Ala-Lys(N-ε-(Palm-Glu-Ot-Bu))-Glu(Ot-Bu)-Phe-Ile-Ala-Trp(Boc)-Leu-Val-Arg(pbf)-Gly-Arg(pbf)-Formula (x)-resin; further preferably, H-His(Trt)-Ala-Glu(Ot-Bu)-HmbGly-Thr(t-Bu)-Phe-Thr(t-Bu)-Ser(t-Bu)-Asp(Ot-Bu)-Val-Ser(t-Bu)-Ser(t-Bu)-Tyr(t-Bu)-Leu-Glu(Ot-Bu)-Gly-Gln(Trt)-Ala-Ala-Lys(N-ε-(Palm-Glu-Ot-Bu))-Glu(Ot-Bu)-Phe-Ile-Ala-Trp(Boc)-Leu-Val-Arg(pbf)-Gly-Arg(pbf)-Formula (x)-AM resin;
wherein the Fmoc protecting group attached to the peptide on the resin is removed before each coupling step.
